RP-L401
Phase 1Biologic
Rocket PharmaceuticalsRP-L401 is one of 10 biologic programs targeting Osteopetrosis. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Osteopetrosis
#DrugCompanyPhaseTrials
1Clolar
GGenzyme, a Sanofi Company
Approved
Rocaltrol
Alnylam PharmaceuticalsPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Interferon-Gamma
SSPP Pharmaclon Ltd.
Phase 3
Fludarabine Monophosphate
SSt. Petersburg State Pavlov Medical University
Phase 3
Campath 1h
Mario Negri Institute for Pharmacological ResearchPhase 3
Busulfex
Akero TherapeuticsPhase 2
Actimmune
HHorizon Therapeutics Ireland DAC
Preclinical
RP-L401
Rocket PharmaceuticalsPhase 1
Systemic Chemotherapy and Antibodies
SSt. Jude Children's Research Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RP-L401. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company